Sustained release tablet containing effective component hydrochloric acid vilazodone

A technology of vilazodone hydrochloride and active ingredients, which is applied in the field of medicine, can solve the problems of poor compliance, large fluctuations in blood drug concentration, and large toxic and side effects in patients with severe depression, so as to reduce the incidence of adverse reactions and reduce medication The effect of frequency and convenience

Inactive Publication Date: 2013-03-06
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Vilazodone hydrochloride is mainly used for the treatment of severe depression in adults. Small-dose ordinary tablets have the disadvantages of frequent medication and poor compliance of patients with severe depression; and ordinary tablets also have large fluctuations in blood drug concentration after administration. Toxicity and side effects are relatively large and other disadvantages, but making vilazodone hydrochloride into sustained-release tablets can overcome many of the above disadvantages, thereby improving the patient's compliance and improving the curative effect of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained release tablet containing effective component hydrochloric acid vilazodone
  • Sustained release tablet containing effective component hydrochloric acid vilazodone
  • Sustained release tablet containing effective component hydrochloric acid vilazodone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1 (1000 pieces amount)

[0032]

[0033] Preparation Process:

[0034] Pass the main ingredient and auxiliary materials through an 80-mesh sieve respectively, and set aside. Weigh the prescription amount of excipients (except hydroxypropyl cellulose 4000cp and magnesium stearate, micropowder silica gel) and mix well with the main ingredient, add soft materials made of binders, granulate with a 20-mesh sieve, dry at 55°C for 18 Mesh sieve for whole grains. Finally, magnesium stearate, micropowder silica gel and hydroxypropyl cellulose are added and mixed evenly, and the intermediate is determined and then compressed into tablets.

Embodiment 2

[0035] Embodiment 2 (quantity of 1000 pieces)

[0036]

[0037] Preparation Process:

[0038] Pass the main ingredient and auxiliary materials through a 60-mesh sieve respectively, and set aside. Weigh the main drug in the prescribed amount and mix it well with the auxiliary materials guar gum, hypromellose, lactose, talcum powder and magnesium stearate in turn, and directly compress the tablet after measuring the intermediate.

Embodiment 3

[0039] Embodiment 3 (quantity of 1000 pieces)

[0040]

[0041] Preparation Process:

[0042] Pass the main ingredient and auxiliary materials through an 80-mesh sieve respectively, and set aside. First weigh the prescription amount of excipients (except hydroxypropyl cellulose 4000cp and talcum powder, micro-powder silica gel) and mix well with the main ingredient, add a soft material made of binder, granulate with a 20-mesh sieve, dry at 55°C, and granulate with a 18-mesh sieve whole grain. Finally, talcum powder, micropowder silica gel and hydroxypropyl cellulose are added and mixed evenly, and the intermediate is determined and then pressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a sustained release tablet containing an effective component hydrochloric acid vilazodone. The sustained release tablet is prepared from the effective component hydrochloric acid vilazodone and sustained release materials; the weight ratio of effective component hydrochloric acid vilazodone to sustained release materials is (1: 0.2)-(1: 20), preferably (1:0.5)-(1:10); and the sustained release material used by the sustained release tablet is one or a combination of several of guar gum, xanthan gum, acrylic resin and cellulose. The hydrochloric acid vilazodone has the characteristics of lasting functions, low toxic and side effects and less medicine-taking times; the release degree in vitro of the sustained release tablet is 8-24 hours; the blood medicine concentration is stable; the occurrence ratio of poor reaction is reduced; the curative effect of the medicines is improved; and the pain of patients is relieved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and more specifically relates to an oral sustained-release tablet containing the active ingredient vilazodone hydrochloride, which is mainly used for the treatment of severe depression in adults. Background technique [0002] Drug Name: Vilazodone Hydrochloride [0003] English name: Vilazodone Hydrochloride [0004] Chemical Name: [0005] 5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamidehydrochloride [0006] Structural formula: [0007] [0008] Molecular formula: C 26 h 27 N 5 o 2 ·HCl [0009] Molecular weight: 477.99 [0010] Depression is a common mental illness. The main reason is that there is too much black bile in the human body, which enters the brain and destroys their activities. The World Health Organization survey found that the global incidence of depression is about 11%, and it has become the fourth largest disease in the world. It is estim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/496A61K47/32A61K47/36A61K47/38A61P25/24
Inventor 王博李洪起任晓文连潇嫣
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap